Shandong Xinhua Pharmaceutical (000756.SZ) has obtained the registration certificate for the suspension of Oseltamivir phosphate and Oseltamivir.

Xinhua Pharmaceutical (000756.SZ) announced that the company recently received the "Drug Registration Certificate" for the approved issuance of oseltamivir phosphate granules for suspension (referred to as "this product" below) from the National Medical Products Administration. This product is used for the treatment of influenza A and B in patients aged 2 weeks and older (oseltamivir phosphate can effectively treat influenza A and B, but there is limited clinical data for the treatment of influenza B). Patients should use the product within 48 hours of the first symptoms appearing. This product can also be used for the prevention of influenza A and B in individuals aged 1 year and older.